A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KN019 in Patients With Active Rheumatoid Arthritis While Receiving Methotrexate
Latest Information Update: 03 Mar 2023
At a glance
- Drugs Belatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Jiangsu Alphamab Biopharmaceuticals
- 28 Feb 2023 Status changed from active, no longer recruiting to completed.
- 29 Mar 2022 According to an Alphamab Oncology media release, the patient enrollment has been completed and the final analysis of clinical results is expected to be completed in the first half of 2022.
- 29 Mar 2022 Status changed from recruiting to active, no longer recruiting, according to an Alphamab Oncology media release.